• Explore /
  • Poster
  • / A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.

A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma.

Abstract Poster

Authors

null

Maria M Rubinstein

Memorial Sloan Kettering Cancer Center, New York, NY

Maria M Rubinstein , Imogen Caird , Qin Zhou , Alexia Iasonos , Claire Frances Friedman , Karen Anne Cadoo , Jason A. Konner , Roisin Eilish O'Cearbhaill , William P. Tew , Dmitriy Zamarin , Rachel N. Grisham , Chrisann Kyi , Krysten Soldan , Stuart M. Lichtman , Louise Ligresti , Sarah J. Schweber , Jasmeet Chadha Singh , Tiffany A. Troso-Sandoval , Carol Aghajanian , Vicky Makker

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

NCT03015129

Citation

J Clin Oncol 37, 2019 (suppl; abstr 5582)

DOI

10.1200/JCO.2019.37.15_suppl.5582

Abstract #

5582

Poster Bd #

405

Abstract Disclosures

Similar Posters

First Author: Taofeek Kunle Owonikoko

First Author: Enrique Grande

First Author: Cesar Augusto Santa-Maria

First Author: Jianqing Zhu